Acknowledgement
We are grateful for the research volunteers, their families, and the investigators at the Alzheimer's Disease Neuroimaging Initiative (ADNI) database. ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd. and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health(www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. The authors thank the application engineers Ying Pei and Huan Liu at GE Medical Systems Corporation for their assistance with MR image postprocessing; and to American Journal Experts (AJE) for their assistance with language editing.
References
- Hou Y, Dan X, Babbar M, Wei Y, Hasselbalch SG, Croteau DL, et al. Ageing as a risk factor for neurodegenerative disease. Nat Rev Neurol 2019;15:565-581 https://doi.org/10.1038/s41582-019-0244-7
- No authors listed. 2020 Alzheimer's disease facts and figures. Alzheimers Dement 2020;16:391-460 https://doi.org/10.1002/alz.12068
- Ngandu T, Lehtisalo J, Solomon A, Levalahti E, Ahtiluoto S, Antikainen R, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet 2015;385:2255-2263 https://doi.org/10.1016/S0140-6736(15)60461-5
- Crous-Bou M, Minguillon C, Gramunt N, Molinuevo JL. Alzheimer's disease prevention: from risk factors to early intervention. Alzheimers Res Ther 2017;9:71
- Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement 2018;14:535-562
- Hwang J, Jeong JH, Yoon SJ, Park KW, Kim EJ, Yoon B, et al. Clinical and biomarker characteristics according to clinical spectrum of Alzheimer's disease (AD) in the validation cohort of Korean Brain Aging Study for the Early Diagnosis and Prediction of AD. J Clin Med 2019;8:341
- Devanarayan P, Devanarayan V, Llano DA; Alzheimer's Disease Neuroimaging Initiative. Identification of a simple and novel cut-point based cerebrospinal fluid and MRI signature for predicting Alzheimer's disease progression that reinforces the 2018 NIA-AA research framework. J Alzheimers Dis 2019;68:537-550 https://doi.org/10.3233/JAD-180905
- Illan-Gala I, Pegueroles J, Montal V, Vilaplana E, CarmonaIragui M, Alcolea D, et al. Challenges associated with biomarker-based classification systems for Alzheimer's disease. Alzheimers Dement (Amst) 2018;10:346-357 https://doi.org/10.1016/j.dadm.2018.03.004
- Altomare D, de Wilde A, Ossenkoppele R, Pelkmans W, Bouwman F, Groot C, et al. Applying the ATN scheme in a memory clinic population: the ABIDE project. Neurology 2019;93:e1635-e1646
- Ebenau JL, Timmers T, Wesselman LMP, Verberk IMW, Verfaillie SCJ, Slot RER, et al. ATN classification and clinical progression in subjective cognitive decline: the SCIENCe project. Neurology 2020;95:e46-e58
- Calvin CM, de Boer C, Raymont V, Gallacher J, Koychev I; European Prevention of Alzheimer's Dementia (EPAD) Consortium. Prediction of Alzheimer's disease biomarker status defined by the 'ATN framework' among cognitively healthy individuals: results from the EPAD longitudinal cohort study. Alzheimers Res Ther 2020;12:143
- Lehmann M, Rohrer JD, Clarkson MJ, Ridgway GR, Scahill RI, Modat M, et al. Reduced cortical thickness in the posterior cingulate gyrus is characteristic of both typical and atypical Alzheimer's disease. J Alzheimers Dis 2010;20:587-598 https://doi.org/10.3233/JAD-2010-1401
- de Jong LW, van der Hiele K, Veer IM, Houwing JJ, Westendorp RG, Bollen EL, et al. Strongly reduced volumes of putamen and thalamus in Alzheimer's disease: an MRI study. Brain 2008;131:3277-3285 https://doi.org/10.1093/brain/awn278
- Cho H, Kim JH, Kim C, Ye BS, Kim HJ, Yoon CW, et al. Shape changes of the basal ganglia and thalamus in Alzheimer's disease: a three-year longitudinal study. J Alzheimers Dis 2014;40:285-295 https://doi.org/10.3233/JAD-132072
- Langa KM, Levine DA. The diagnosis and management of mild cognitive impairment: a clinical review. JAMA 2014;312:2551-2561 https://doi.org/10.1001/jama.2014.13806
- Vos SJ, Verhey F, Frolich L, Kornhuber J, Wiltfang J, Maier W, et al. Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. Brain 2015;138:1327-1338 https://doi.org/10.1093/brain/awv029
- Ekman U, Ferreira D, Westman E. The A/T/N biomarker scheme and patterns of brain atrophy assessed in mild cognitive impairment. Sci Rep 2018;8:8431
- McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944 https://doi.org/10.1212/WNL.34.7.939
- Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007;6:734-746 https://doi.org/10.1016/S1474-4422(07)70178-3
- Liem F, Merillat S, Bezzola L, Hirsiger S, Philipp M, Madhyastha T, et al. Reliability and statistical power analysis of cortical and subcortical FreeSurfer metrics in a large sample of healthy elderly. Neuroimage 2015;108:95-109 https://doi.org/10.1016/j.neuroimage.2014.12.035
- Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991;30:572-580 https://doi.org/10.1002/ana.410300410
- Sorensen L, Igel C, Liv Hansen N, Osler M, Lauritzen M, Rostrup E, et al. Early detection of Alzheimer's disease using MRI hippocampal texture. Hum Brain Mapp 2016;37:1148-1161 https://doi.org/10.1002/hbm.23091
- Luk CC, Ishaque A, Khan M, Ta D, Chenji S, Yang YH, et al. Alzheimer's disease: 3-dimensional MRI texture for prediction of conversion from mild cognitive impairment. Alzheimers Dement (Amst) 2018;10:755-763
- Huang K, Lin Y, Yang L, Wang Y, Cai S, Pang L, et al. A multipredictor model to predict the conversion of mild cognitive impairment to Alzheimer's disease by using a predictive nomogram. Neuropsychopharmacology 2020;45:358-366 https://doi.org/10.1038/s41386-019-0551-0
- Shinde S, Prasad S, Saboo Y, Kaushick R, Saini J, Pal PK, et al. Predictive markers for Parkinson's disease using deep neural nets on neuromelanin sensitive MRI. Neuroimage Clin 2019;22:101748
- Li G, Zhai G, Zhao X, An H, Spincemaille P, Gillen KM, et al. 3D texture analyses within the substantia nigra of Parkinson's disease patients on quantitative susceptibility maps and R2* R2* maps. Neuroimage 2019;188:465-472 https://doi.org/10.1016/j.neuroimage.2018.12.041
- Geroldi C, Rossi R, Calvagna C, Testa C, Bresciani L, Binetti G, et al. Medial temporal atrophy but not memory deficit predicts progression to dementia in patients with mild cognitive impairment. J Neurol Neurosurg Psychiatry 2006;77:1219-1222 https://doi.org/10.1136/jnnp.2005.082651
- Fennema-Notestine C, Hagler DJ Jr, McEvoy LK, Fleisher AS, Wu EH, Karow DS, et al. Structural MRI biomarkers for preclinical and mild Alzheimer's disease. Hum Brain Mapp 2009;30:3238-3253 https://doi.org/10.1002/hbm.20744
- Whitwell JL, Przybelski SA, Weigand SD, Knopman DS, Boeve BF, Petersen RC, et al. 3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer's disease. Brain 2007;130:1777-1786
- Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA, Cummings JL. Alzheimer's disease. Nat Rev Dis Primers 2015;1:15056
- Jacobs HI, Van Boxtel MP, Jolles J, Verhey FR, Uylings HB. Parietal cortex matters in Alzheimer's disease: an overview of structural, functional and metabolic findings. Neurosci Biobehav Rev 2012;36:297-309
- Horinek D, Varjassyova A, Hort J. Magnetic resonance analysis of amygdalar volume in Alzheimer's disease. Curr Opin Psychiatry 2007;20:273-277
- Tang X, Holland D, Dale AM, Miller MI; Alzheimer's Disease Neuroimaging Initiative. APOE affects the volume and shape of the amygdala and the hippocampus in mild cognitive impairment and Alzheimer's disease: age matters. J Alzheimers Dis 2015;47:645-660 https://doi.org/10.3233/JAD-150262
- Golde TE, Eckman CB, Younkin SG. Biochemical detection of Abeta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease. Biochim Biophys Acta 2000;1502:172-187 https://doi.org/10.1016/S0925-4439(00)00043-0
- Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 2012;69:98-106 https://doi.org/10.1001/archgenpsychiatry.2011.155
- Jack CR Jr, Knopman DS, Weigand SD, Wiste HJ, Vemuri P, Lowe V, et al. An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol 2012;71:765-775 https://doi.org/10.1002/ana.22628
- Sonnen JA, Larson EB, Crane PK, Haneuse S, Li G, Schellenberg GD, et al. Pathological correlates of dementia in a longitudinal, population-based sample of aging. Ann Neurol 2007;62:406-413
- James BD, Wilson RS, Boyle PA, Trojanowski JQ, Bennett DA, Schneider JA. TDP-43 stage, mixed pathologies, and clinical Alzheimer's-type dementia. Brain 2016;139:2983-2993 https://doi.org/10.1093/brain/aww224